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Abstract 
 
 Phospholemman (PLM), a member of the FXYD family of regulators of ion transport, is 
a major sarcolemmal substrate for protein kinases A and C in cardiac and skeletal muscle. In the 
heart, PLM co-localizes and co-immunoprecipitates with Na+-K+-ATPase, Na+/Ca2+ exchanger 
and L-type Ca2+ channel. Functionally, when phosphorylated at serine68, PLM stimulates Na+-
K+-ATPase but inhibits Na+/Ca2+ exchanger in cardiac myocytes. In heterologous expression 
systems, PLM modulates the gating of cardiac L-type Ca2+ channel. Therefore, PLM occupies a 
key modulatory role in intracellular Na+ and Ca2+ homeostasis and is intimately involved in 
regulation of excitation-contraction (EC) coupling.  Genetic ablation of PLM results in a slight 
increase in baseline cardiac contractility and prolongation of action potential duration.  When 
hearts are subjected to catecholamine stress, PLM minimizes the risks of arrhythmogenesis by 
reducing Na+ overload and simultaneously preserves inotropy by inhibiting Na+/Ca2+ exchanger.  
In heart failure, both expression and phosphorylation state of PLM are altered and may partly 
account for abnormalities in EC coupling.  The unique role of PLM in regulation of Na+-K+-
ATPase, Na+/Ca2+ exchanger and potentially L-type Ca2+ channel in the heart, together with the 
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changes in its expression and phosphorylation in heart failure, make PLM a rational and novel 
target for development of drugs in our armamentarium against heart failure. 
 
 
 
 
 
 
Introduction 
     Phospholemman (PLM) was initially identified by Larry Jones in 1985 (58) as a 15-
kDa sarcolemmal (SL) protein that is phosphorylated in response to isoproterenol and is distinct 
from phospholamban (PLB)(58). Follow-up studies indicated that this 15-kDa SL protein is also 
phosphorylated by protein kinase (PK) C (59) and α-adrenergic agonists (38). In 1991, this 15-
kDa SL phosphoprotein was purified, the complete protein sequence determined by Edman 
degradation, the cDNA cloned, and the name “phospholemman” was coined (53). In 1997, the 
human PLM gene is localized to chromosome 19q13.1 (11).  
PLM is synthesized as a 92 amino acid peptide containing at its N-terminus a 20 amino 
acid signal peptide which is cleaved off during processing. The mature protein contains 72 amino 
acid residues with a calculated molecular weight of 8409, but a mobility of ~15 kDa in SDS-
PAGE gels. The first 17 amino acid residues lie in the extracellular domain. The transmembrane 
(TM) region contains 20 amino acids (residues 18-37) while the remaining 35 amino acids 
(residues 38-72) at the C-terminus are in the cytoplasm. Palmer et al. (53) also noted sequence 
homology between PLM and γ-subunit of Na+-K+-ATPase, as well as a short region of sequence 
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similarity between PLM (at its C-terminus facing the cytoplasm) and PLB (at its N-terminus also 
facing the cytoplasm). This region of sequence similarity (RSSIRRLST69 in PLM and 
RSAIRRAST17 in PLB) contains serines and threonines that are potential phosphorylation sites. 
Indeed, serine68 in PLM and serine16 in PLB are phosphorylated by PKA (67, 79).   
 The extracellular N-terminus of PLM contains a FXYD motif, and the cytoplasmic tail of 
dog, human and rat PLM contains 3 serines (at residues 62, 63 and 68) and 1 threonine (at 
residue 69) but threonine69 is replaced by serine in mouse PLM. By nuclear magnetic resonance 
(NMR) (23) and infrared spectroscopy (2), the TM domain of PLM reconstituted in liposomes is 
an α-helix with a maximum tilt of 15-170.  Specifically, NMR spectroscopic studies of highly 
purified PLM in model micelles indicate that the molecule consists of 4 α-helices: H1 (residues 
12-17) is in the extracellular N-terminus, H2 (residues 22-38) is the main TM helix followed by 
the short H3 (residues 39-45), and H4 (residues 60-68) in the C-terminus is connected to H3 by a 
flexible linker (Fig. 1)(76).  In vivo, PKA phosphorylates serine68 while PKC phosphorylates 
serine63 and serine68 of PLM (79). In vitro studies using PLM fragments suggest that PKA also 
phosphorylates serine63 while PKC phosphorylates threonine69 (25). In adult rat myocytes, ∼46% 
of serine68 and ∼16% of serine63 are estimated to be phosphorylated in the resting state (69).  
Using phospho-specific anti-PLM antibodies (25, 62), ∼30-40% of PLM in adult rat myocytes 
(25, 89) and ∼25% of PLM in guinea pig myocytes (66) are phosphorylated under basal 
conditions. In transfected HEK293 cells, ∼30-45 % of exogenous PLM is phosphorylated under 
resting conditions (92).   
 Based on observations on Xenopus oocytes in which PLM is overexpressed, Randall 
Moorman suggested that PLM is a hyperpolarization-activated anion-selective channel (46).  
When reconstituted in lipid bilayers, PLM forms a channel that is highly selective for taurine 
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(12) and is thought to be involved in regulation of cell volume in non-cardiac tissues (15, 47).  
The function of PLM in the heart remains unknown until the dawning of the 21st century. 
Phospholemman: Founding Member of the FXYD Family of Regulators of Ion Transport 
 In 2000, Kathy Sweadner described the FXYD family of regulators of ion transport (73), 
of which PLM is the first cloned member (FXYD1). At present, there are at least 12 known 
FXYD proteins, including γ-subunit of Na+-K+-ATPase (FXYD2), mammary associated tumor 8 
kDa (MAT-8 or FXYD3), channel inducing factor (CHIF or FXYD4), dysadherin (FXYD5; also 
known as related to ion channel RIC), phosphohippolin (FXYD6), FXYD7, and PLM-S 
(FXYD10; the shark homolog of PLM). As a family, FXYD proteins are found predominantly in 
tissues involved in solute and fluid transport (kidney, colon, pancreas, mammary gland, liver, 
lung, prostate and placenta) or are electrically excitable (heart, skeletal and neural tissues).  All 
FXYD members have the signature FXYD motif in the N-terminus and a single TM domain. 
Except for γ-subunit of Na+-K+-ATPase, all other known members of the FXYD gene family has 
at least one serine or threonine within the cytoplasmic tail, indicating potential phosphorylation 
sites. PLM is unique among FXYD proteins in that it has consensus sequence for 
phosphorylation by PKA (RRXS), PKC (RXXSXR) and never-in-mitosis aspergillus (NIMA) 
kinase (FRXS/T).  PLM is also a substrate for myotonic dystrophy protein kinase (48).  The γ-
subunit of Na+-K+-ATPase is the only member in the FXYD family boasting two alternative 
splice variants (FXYD2a and FXYD2b). 
Phospholemman: Regulator of Cardiac Na+-K+-ATPase 
 In 2002, Kaethi Geering demonstrated that PLM co-immunoprecipitates with α-subunits 
of Na+-K+-ATPase in bovine sarcolemma (14). In isolated adult rat cardiac myocytes, PLM co-
localizes with α-subunits of Na+-K+-ATPase (Fig. 2). When co-expressed with α- and β-subunits 
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of Na+-K+-ATPase in Xenopus oocytes, PLM modulates Na+-K+-ATPase activity primarily by 
decreasing Km for Na+ and K+ without affecting Vmax (14). Data obtained from cardiac myocytes 
or homogenates indicate that PLM inhibits Na+-K+-ATPase by reducing its apparent affinities for 
intracellular Na+ (9, 17) and external K+ (29) or decreasing Vmax (3, 24, 25, 28, 55, 66, 70, 80, 
89). When phosphorylated at serine68, PLM relieves its inhibition on Na+-K+-ATPase by 
decreasing its apparent Km for Na+ (17, 80) but not for K+ (29) and increasing Vmax (24, 66, 80) .  
In terms of molecular interactions between PLM and Na+-K+-ATPase, mutational 
analysis suggests that FXYD proteins (FXYD2, 4 and 7) interact with TM9 segment of Na+-K+-
ATPase (36).  Co-immunoprecipitation and covalent cross-linking studies demonstrate the TM 
segment of PLM is close to TM2 segment of Na+-K+-ATPase (39).  Molecular modeling based 
on Ca2+-ATPase crystal structure in the E1ATP-bound conformation suggests that the single TM 
segment of FXYD proteins docks into the groove between TM segments 2, 6 and 9 of the α-
subunit of Na+-K+-ATPase (39).  High resolution crystal structure (2.4 Angstrom) of shark rectal 
gland Na+-K+-ATPase in the E2.2K+.Pi state indicates that FXYD proteins interact almost 
exclusively with the outside of TM9 of the α-subunit (65).  The role of the signature FXYD(Y) 
motif is to stabilize interactions between α- and β-subunits of Na+-K+-ATPase and residue D (in 
the FXYD motif) caps the helix and defines the membrane border (65).   In transfected HEK293 
cells, PLM interacts with either α1- or α2-subunit of Na+-K+-ATPase in a 1:1 stoichiometry (9).  
Phosphorylation of PLM-S causes it to dissociate from shark Na+-K+-ATPase (42).  However, 
phosphorylation of PLM did not cause it to dissociate from the α-subunit of Na+-K+-ATPase (9, 
66). Despite NMR studies of PLM in micelles showing no major conformational changes on 
phosphorylation of serine68 (77), in intact cells examined with fluorescence resonance energy 
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transfer (FRET), interaction between PLM and Na+-K+-ATPase is decreased on phosphorylation 
of PLM (9, 10). 
There are 4 isoforms of the catalytic α-subunits of Na+-K+-ATPase and expression of a 
particular α-isoform is both tissue- and species-dependent (7).  Human (43, 85) and rabbit (8) 
hearts are known to express α1-, α2- and α-3 isoforms while rodent hearts express only α1- 
(ouabain-resistant) and α2-isoforms of Na+-K+-ATPase (4, 66, 72, 80).  In both adult rat and 
mouse ventricles, the ouabain-sensitive α2-subunit is preferentially localized to the t-tubules (4, 
74) and its activity represents <25% of total Na+-K+-ATPase activities (4, 72, 80).  PLM co-
immunoprecipitates all 3 α-subunits of Na+-K+-ATPase in human and rabbit (8),  α1- and α2-
subunits in mouse (80) and bovine (14), but only α1-subunit in rat (24) and guinea pig (66) 
hearts. In both wild-type (WT) mouse (80) and guinea pig (66) ventricular myocytes, PLM 
regulates the activity of α1- but not α2-isoform of Na+-K+-ATPase.  This conclusion must be 
tempered with the recent finding that in “SWAP” mouse (21) in which the ouabain affinities of 
the α-subunits are reversed, PLM regulates the apparent affinities for Na+ of both α1- and α2-
subunitis of Na+-K+-ATPase (9).  Together with observations made on Xenopus oocytes 
heterologously expressing PLM and Na+-K+-ATPase (6, 14), it is likely the PLM regulates both 
α1- and α2-subunits of Na+-K+-ATPase.       
Cardiac Excitation-Contraction Coupling 
 Both α1- (21) and α2-subunits (74) of Na+-K+-ATPase have been implicated in the 
control of cardiac contractility. Therefore, modulation of Na+-K+-ATPase activity suggests an 
important role for PLM in regulation of inotropy.  We will give a brief overview of cardiac 
excitation-contraction coupling (Fig. 3) which has previously been reviewed by Don Bers in 
detail (5).  During the upstroke of the action potential, Na+ enters via Na+ channels and further 
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depolarizes the sarcolemma. Depolarization activates the voltage-dependent L-type Ca2+ 
channels, allowing extracellular Ca2+ to enter as an inward current (ICa), which contributes to the 
plateau phase of the action potential.  Some Ca2+ also enters via the Na+/Ca2+ exchanger (NCX1) 
operating in the reverse mode (3 Na+ out: 1 Ca2+ in) during this phase of the action potential, 
although the amount and duration of Ca2+ influx via reverse Na+/Ca2+ exchange vary among 
species.  Ca2+ entry triggers release of ∼2/3 of Ca2+ stored in the sarcoplasmic reticulum (SR) via 
the ryanodine receptor (RyR2).  The combination of Ca2+ influx and SR Ca2+ release abruptly 
raises the free intracellular Ca2+ concentration ([Ca2+]i), allowing Ca2+ to bind to troponin C and 
activate the contractile apparatus.  Relaxation requires termination of SR Ca2+ release, and 
[Ca2+]i to decline so that Ca2+ can dissociate from troponin C. About 70-92% of myoplasmic 
Ca2+ is re-sequestered into the SR by sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2) 
which is under the control of PLB.  To maintain steady-state Ca2+ balance, Ca2+ that has entered 
during systole is mainly extruded by NCX1 operating in the forward mode (3 Na+ in: 1 Ca2+ out), 
with the sarcolemmal Ca2+-ATPase playing a smaller role.  Likewise, the small amount of Na+ 
that has entered during depolarization is extruded by Na+-K+-ATPase during diastole. In this 
way, the cardiac myocyte maintains beat-to-beat Ca2+ and Na+ balance.  Outward K+ currents 
contribute to repolarization phase of the action potential.   
 Among the many transporters and ion channels involved in cardiac Ca2+ fluxes, NCX1 is 
unique in that during an action potential, it participates in Ca2+ influx, [Ca2+]i transient buffering 
and Ca2+ efflux (5).  The direction of Ca2+ flux (in or out) depends on the thermodynamic driving 
force determined by the membrane potential (Em) and the concentrations of Na+ and Ca2+ ions 
sensed by NCX1.  Other than the determinants of its thermodynamic driving force, remarkably 
little is known about the regulation of NCX1. 
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  In the heart, inhibition of Na+-K+-ATPase by PLM is expected to raise intracellular Na+ 
concentration ([Na+]i), thereby decreasing the thermodynamic driving force for forward Na+/Ca2+ 
exchange (Ca2+ efflux) and increasing the driving force for reverse Na+/Ca2+ exchange (Ca2+ 
influx).  Both these actions are expected to increase [Ca2+]i and SR Ca2+ load, thereby enhancing 
cardiac contractility.  Indeed, inhibition of Na+-K+-ATPase with secondary effects on NCX1 has 
long been proposed to be the mechanism of positive inotropy of digitalis glycosides (27). 
Phospholemman: First Endogenous Regulator of Cardiac Na+/Ca2+ Exchanger 
      When PLM is overexpressed (1.4 to 3.5-fold) in adult rat left ventricular (LV) myocytes 
by adenovirus-mediated gene transfer (68, 89, 90),  expression of SERCA2, α1- and α2-subunits 
of Na+-K+-ATPase, NCX1 and calsequestrin remains unchanged. As expected, Na+-K+-ATPase 
current (Ipump) is decreased in rat myocytes overexpressing PLM, primarily as a result of decrease 
in Vmax rather than changes in apparent Km for Na+ and K+ (89). A totally unexpected finding is 
that both contraction and [Ca2+]i transient amplitudes (5.0 mM [Ca2+]o, 1 Hz, 370C) in myocytes 
overexpressing PLM are lower, rather than higher, when compared to control rat myocytes 
overexpressing green fluorescent protein (GFP)(68).  This serendipitous but critical observation 
is inconsistent with the theoretical prediction that inhibition of Na+-K+-ATPase by PLM leads to 
enhanced cardiac contractility.  Because the contractile phenotype of myocytes overexpressing 
PLM is similar to that observed in myocytes in which NCX1 is downregulated (75), and opposite 
to that in which NCX1 is overexpressed (91), we were the first to propose in 2002 that PLM 
directly regulates NCX1 activity, independent of its effects on Na+-K+-ATPase (68).  Follow-up 
studies in adult rat myocytes demonstrate that PLM co-localizes with NCX1 to the sarcolemma 
and t-tubules (90), that PLM co-immunoprecipitates with NCX1 (1, 45), that overexpression of 
PLM inhibits Na+/Ca2+ exchange current (INaCa)(69, 90), and that downregulation of PLM by 
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antisense increases INaCa (45).  Using HEK293 cells that are devoid of NCX1 and PLM, we 
demonstrated that cells transfected with NCX1 display the characteristic INaCa, and that cells co-
transfected with PLM demonstrate inhibition of INaCa as well as Na+-dependent Ca2+ uptake (1).  
In addition, PLM co-immunoprecipitates with NCX1 in transfected HEK293 cells (1), pig 
sarcolemmal vesicles (1) and guinea pig ventricular myocyte membranes (82).  In cardiac 
myocytes isolated from PLM-null mice, INaCa was higher in PLM-null myocytes (87) despite no 
differences in NCX1 protein levels (78).  The cumulative evidence obtained from 3 model 
systems: adult rat myocytes, HEK293 cells and PLM-null mice are all consistent with our 
hypothesis that PLM directly regulates NCX1 (13). 
 NCX1 is a 938 amino acid (939 amino acid in the rat) peptide consisting of an 
extracellular N-terminal domain comprising the 1st 5 TM segments, a large intracellular loop 
(residues 218-764), and an intracellular C-terminal domain consisting of the last 4 TM segments 
(52, 56).  The α-repeats of TM segments 2, 3 and 7 of NCX1 are important in ion transport 
activity (31, 51) while the large intracellular loop contains the regulatory domains of the 
exchanger (35, 37, 40).  Using glutathione S-transferase (GST) pulldown assay, we demonstrated 
that neither the N- nor the C-terminal TM domains of NCX1 associates with PLM (81).  Rather, 
the cytoplasmic tail of PLM both physically and functionally interacts with the intracellular loop 
(residues 218-358) of NCX1 (81). Using overlapping NCX1 loop deletion mutants, we further 
showed that PLM interacts with NCX1 at 2 distinct regions encompassing residues 238-270 and 
300-328 (92). 
 There are significant differences between the mechanisms by which PLM regulates the 
activities of NCX1 and Na+-K+-ATPase.  First, phosphorylation of PLM at serine68 relieves its 
inhibition of Na+-K+-ATPase (17, 24, 66). By contrast, PLM phosphorylated at serine68 is the 
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active species that inhibits NCX1 (69, 87).  Second, the TM segment of FXYD proteins (and by 
inference PLM) interacts with TM segments 2, 6 and 9 of α-subunit of Na+-K+-ATPase (36, 39, 
65). By contrast, TM43, a PLM mutant with its cytoplasmic tail truncated, targets correctly to the 
sarcolemma (69) but does not co-immunoprecipitate NCX1 (81) and has no effect on myocyte 
contractility (69), suggesting little-to-no association between the TM domains of PLM and 
NCX1. 
Phospholemman: Regulator of Cardiac L-type Calcium Channel 
 In guinea pig cardiac myocytes, Blaise Peterson recently demonstrated that PLM co-
immunoprecipitates not only NCX1 but also L-type Ca2+ channels (Cav1.2)(82).  In transfected 
HEK293 cells and using Ba2+ as charge carrier, PLM modulates gating kinetics of Cav1.2 but not 
Cav2.1 (P/Q-type) or Cav2.2 (N-type) Ca2+ channels (82). Specifically, PLM was found to 
modulate 4 important gating processes of Cav1.2 channels: (i) activation kinetics were slowed at 
voltages near the threshold for channel activation; (ii) deactivation kinetics were slowed 
following voltage steps mimicking human cardiac action potential; (iii) voltage-dependent 
inactivation was enhanced at voltages corresponding to the plateau phase of the cardiac action 
potential; and (iv) increased number of channels enter a deep inactivated state from which 
recovery is slow.  When a human cardiac action potential is imposed on HEK293 cells 
transfected with Cav1.2 channels, PLM increases Ca2+ influx during the repolarization phase of 
the cardiac action potential (82). The role of PLM phosphorylation in the regulation of Cav1.2 
gating kinetics remains to be elucidated. 
The possibility that in cardiac myocytes, PLM may potentially modulate gating kinetics 
of L-type Ca2+ channels, in addition to its known effects on Na+-K+-ATPase and Na+/Ca2+ 
exchanger, renders the interpretation of the effects of PLM expression/phosphorylation on 
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cardiac contractility extremely complex.  However, heterologous expression systems often do 
not reproduce a protein’s native milieu and may distort the stoichiometry of interaction between 
proteins. A good example is the potentiation of ICa by adrenergic agonists, so readily observed in 
cardiac myocytes (63, 88), has yet to be reproduced in heterologous expression systems (34). In 
addition, using Ca2+ as charge carrier, we did not detect any differences in maximal ICa 
amplitude, fast and slow inactivation time constants, slope conductance and test potential at 
which maximal ICa occurs between WT and PLM-null myocytes (78). Therefore, the 
physiological significance of regulation of Cav1.2 by PLM, while intriguing, remains to be 
established in cardiac myocytes. 
Regulation of Single Myocyte Contraction by Phospholemman: Na+-K+-ATPase vs. NCX1 
 In cultured myocytes isolated from PLM-null mice and expressing the phosphomimetic 
PLM S68E mutant, INaCa but not Ipump is inhibited (70). This is associated with decreased [Ca2+]i 
transient and contraction amplitudes (1 Hz, 370C) measured at 5.0 but not at 1.8 mM [Ca2+]o: the 
phenotype that we observed when NCX1 is downregulated (75) or when PLM is overexpressed 
(68).  By contrast, when cultured PLM-null myocytes overexpress the non-phosphorylable PLM 
S68A mutant, Ipump but not INaCa is inhibited (70). This is associated with no changes in [Ca2+]i 
transient and contraction amplitudes at both [Ca2+]o.  Therefore, under conditions in which 
[Ca2+]o is varied to manipulate the thermodynamic driving force for NCX1, regulation of single 
cardiac myocyte contractility by PLM is mediated by its inhibitory effects on NCX1 rather than 
Na+-K+-ATPase.   
When myocytes are subjected to rapid pacing (2 Hz) and isoproterenol (1 µM) 
stimulation, [Na+]i initially increases but then starts to decline in WT but not in PLM-null 
myocytes (18, 80).  [Ca2+]i transient and contraction amplitudes follow the time course of [Na+]i: 
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initially increase followed by decline in WT but not PLM-null myocytes. When pacing was 
slowed to 0.5 Hz to minimize the steep rise in [Na+]i, both [Ca2+]i transient and contraction 
amplitudes increase to a lower steady-state level without any time-dependent decline in both WT 
and PLM-null myocytes (80).  These observations suggest that under conditions of high [Na+]i, 
phosphorylated PLM activates Na+-K+-ATPase to limit intracellular Na+ overload at the expense 
of reduced inotropy.  Therefore, at the level of a single myocyte, PLM can be shown to regulate 
Na+ and Ca2+ fluxes (and hence [Ca2+]i transients and contractility), by either NCX1 or Na+-K+-
ATPase, depending on experimental manipulations. 
Regulation of In Vivo Contractility by Phospholemman: Studies with PLM-null Mice 
In 2005, Amy Tucker made a major contribution to the understanding of PLM and 
cardiac function by successfully engineering the PLM-null mouse (32).  There is mild cardiac 
hypertrophy (3, 32, 80), at least partly due to increased fibrosis in PLM-null hearts (80) since 
neither LV myocyte length and width (78) nor whole cell membrane capacitance (a measure of 
cell surface area)(17, 78) is different between WT and PLM-null myocytes.  There are no 
differences in protein levels of α1-, α2-, β1- and β2-subunits of Na+-K+-ATPase, SERCA2, 
PLB, NCX1 and calsequestrin between wild-type and congenic PLM-null hearts (3, 78).  The 
majority of proteins that are differentially expressed between WT and PLM-null hearts are 
involved in cell metabolism (3). Na+-K+-ATPase enzymatic activity (3), Ipump (17, 70) and INaCa 
(70, 87) are higher in PLM-null hearts, as expected from the relief of inhibition of Na+-K+-
ATPase and NCX1. There are no changes in ICa amplitudes but action potential duration is 
prolonged in PLM-null myocytes (78).  
The effects of PLM on cardiac contractility in vivo are complicated and controversial. 
Using magnetic resonance imaging, Amy Tucker (32) initially reported cardiac hypertrophy and 
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increased ejection fraction in PLM-null hearts of mice with mixed genetic background (C57BL/6 
and 129/SvJ). By contrast, in vivo hemodynamic measurements made by Mike Shattock with 
conductance catheter introduced by LV puncture in open-chest mice demonstrate no significant 
differences in measured cardiac indices between WT and PLM-null mice of congenic (C57BL/6) 
background (3). Our own data in closed-chest catheterized mice show slightly increased baseline 
+dP/dt in congenic PLM-null hearts (80).  Different genetic backgrounds, non-invasive imaging 
vs. invasive catheterization, different anesthesia, blood loss associated with opening the chest 
and LV puncture, and heat dissipation in an open-chest mice, may account for these 
discrepancies.  The weight of current evidence, however, indicates that PLM-null hearts contract 
just as well, if not better, than WT hearts.  This is inconsistent with the expectation that with 
relief of inhibition of Na+-K+-ATPase, PLM-null hearts should exhibit lower contractility when 
compared to WT hearts.  
Phospholemman: a Novel Cardiac Stress Protein 
 When PLM is overexpressed in adult rat LV myocytes, contractility and [Ca2+]i transient 
amplitudes measured under physiological conditions (1.8 mM [Ca2+]o, 1 Hz, 370C) are only 
slightly less than those measured in control myocytes expressing GFP (68).  Likewise, 
contractility and [Ca2+]i transient amplitudes (1.8 mM [Ca2+]o, 1 Hz, 370C) are similar between 
WT and PLM-null myocytes (78).  Only when the thermodynamic driving force for NCX1 is 
altered by varying [Ca2+]o (0.6 or 5.0 mM) are the effects of PLM on myocyte contractility and 
[Ca2+]i transients evident (45, 68, 69, 78, 90).  The effects of PLM on Na+-K+-ATPase are also 
not apparent in myocytes under resting conditions: basal [Na+]i is similar between wild-type and 
PLM-null myocytes (17, 80).  Therefore, under resting conditions, PLM is functionally 
quiescent. 
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 In the intact heart, β-adrenergic stimulation increases chronotropy leading to more 
frequent depolarizations and increased Na+ entry.  In addition, ICa and SERCA2 activity are also 
increased in response to β-adrenergic stimulation, resulting in increased Ca2+ entry and SR Ca2+ 
loading. Elevated SR Ca2+ content available for release largely accounts for the enhanced 
inotropy associated with β-adrenergic stimulation.  Increased Ca2+ entry must be balanced by 
greater Ca2+ efflux mediated by forward NCX1, thereby bringing more Na+ into the myocyte.  
This, if unchecked, will lead to cellular Na+ and Ca2+ overload. Don Bers (18) hypothesized that 
β-adrenergic agonists increase PLM phosphorylation at serine68, thereby activating Na+-K+-
ATPase and resulting in lower [Na+]i.  The lower [Na+]i promotes Ca2+ efflux via NCX1, 
resulting in lower [Ca2+]i transient and contraction amplitudes (18, 80).  Indeed, when hearts in 
vivo are stressed with maximal doses of isoproterenol, inotropy (+dP/dt) rises to a peak within 2 
minutes followed by decline in WT but not PLM-null hearts (Fig. 4).  Therefore, when hearts are 
under duress, one of the major functions of PLM is to limit Na+ and Ca2+ overload, thereby 
minimizing the risks of arrhythmogenesis apparently at the expense of reduced inotropy. 
 On the other hand, reduced cardiac contractility under conditions of fight or flight is 
clearly not in the best interests of the organism.  In 2006 we proposed a coordinated paradigm in 
which PLM, upon phosphorylation at serine68, enhances Na+-K+-ATPase activity to minimize 
risks of arrhythmogenesis but inhibits Na+/Ca2+ exchanger to preserve inotropy during stress 
(87).  Our recent experiments provide support for this hypothesis.  In PLM-null hearts in which 
isoproterenol has little-to-no effects on Na+-K+-ATPase (17, 80), injection of recombinant adeno-
associated virus (serotype 9) expressing the phosphomimetic PLM S68E mutant (rAAV9-S68E) 
directly into the LV resulted in expression of the mutant protein after 4-5 weeks.  PLM S68E 
mutant inhibits NCX1 but not Na+-K+-ATPase (70). Isoproterenol stimulation resulted in similar 
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increases in [Na+]i but higher +dP/dt in PLM-null hearts expressing PLM S68E mutant when 
compared to PLM-null hearts expressing GFP (Fig. 5). Therefore, inhibition of NCX1 by 
phosphorylated PLM preserves cardiac contractility under stressful situations. 
FXYD Proteins in Aging, Exercise and Disease  
 PLM expression is 2-fold higher in neonatal rabbit ventricular membranes and declines 
within 10 days to the level observed in adults (71).  The decrease in PLM expression with 
postnatal maturation is concurrent with reduction in Na+-K+-ATPase and Na+/Ca2+ exchanger 
(71) and suggests tight coordination of PLM with the 2 ion transporters.  With aging, expression 
of PLM in sedentary rat skeletal muscle is not altered but the level of α1-subunit of Na+-K+-
ATPase that co-immunoprecipitates with PLM increases 3-fold (61). There are no detectable 
changes of association of α2-subunit of Na+-K+-ATPase with PLM with aging (61). 
Acute exercise (treadmill running) in rats increases sarcolemmal PLM in skeletal muscle 
by 200-350% due to translocation, but phosphorylation at serine68 appears not the be altered (60).  
When senescent rats (26 months-old) are subjected to endurance treadmill running for 13-14 
weeks, PLM in skeletal muscle is increased by 150% when compared to sedentary senescent rats 
(61).  In addition, increased association of PLM with α1-subunit of Na+-K+-ATPase in skeletal 
muscle of senescent rats (as compared to young rats) is decreased with endurance treadmill 
running (61). 
In 2002, using cDNA microarrays containing 86 known genes and 989 unknown cDNAs, 
Sehl et al. (64) are the first to report that PLM is 1 of only 19 genes to increase after myocardial 
infarction (MI) in the rat.  We confirmed that PLM protein levels increased 2.4- and 4-fold at 3 
and 7 days post-MI, respectively, in the rat (89).  PLM overexpression may very well explain the 
depression in both Na+-K+-ATPase (20) and Na+/Ca2+ exchanger (19, 86) activities observed in 
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the post-MI rat model.  In rat hearts subjected to acute ischemia, PLM is phosphorylated which 
leads to profound activation of sarcolemmal Na+-K+-ATPase (24).  In isolated perfused mouse 
hearts subjected to ischemia/reperfusion, protection against infarction by sildenafil is associated 
with increased PLM phosphorylation at serine69 which enhances Na+-K+-ATPase activity during 
reperfusion (41). Increased Na+-K+-ATPase activity during acute ischemia ± reperfusion is 
critical in maintaining [Na+]i homeostasis in order to minimize the adverse effects of elevated 
[Na+]i on contractility and arrhythmogenesis. In human heart failure, protein levels of PLM in 
LV homogenates are reduced by 24% (8).  In a rabbit model of volume overload heart failure 
which is prone to arrhythmias (57), expression of PLM is reduced by 42-48% but 
phosphorylation at serine68 is dramatically increased (8). Thus, both altered expression and 
phosphorylation of PLM have been observed in various cardiac disease models. In this context, it 
is very relevant to note that the 2 classes of drugs that have been clinically proven to be 
efficacious in human heart failure, β-adrenergic blockers (lowering PKA activity) and 
angiotensin converting enzyme inhibitors (reducing PKC activity), both have PLM as a common 
target. 
Sepsis is a major clinical problem which is characterized by profound hypotension, 
systemic vasodilatation and depression in cardiac contractility. A wide range of inflammatory 
cascades is activated during systemic sepsis (54). Increased nitric oxide (NO) by inducible NO 
synthase (iNOS) has been suggested to cause depressed cardiac contractility in sepsis (26).  In 
this light, Helge Rasmussen demonstrated that NO stimulates Na+-K+-ATPase (22, 83) and Mike 
Shattock reported (in abstract form) that this is dependent on PLM. Acceleration of Na+-K+-
ATPase activity by PLM may account for hyperpolarization and relaxation of vascular smooth 
muscle (vasodilatation) in addition to depression of cardiac contractility. 
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PLM has also been implicated in other diseases.  For example, PLM is downregulated in 
layer II/III stellate neurons in patients with schizophrenia (30).  Rett syndrome, an X-linked 
neuro-development disorder that ranks as the second most prevalent cause of mental retardation 
in girls (49), is due to heterozygous de novo mutations in the methyl-CpG-binding protein 2 
(MeCP2) gene.  MeCP2 normally represses PLM transcription through direct interactions with 
sequences in the PLM promoter.  In patients with Rett syndrome and MeCP2-null mice, PLM is 
elevated in neurons in the frontal cortex and cerebellum (16, 33). Increasing neuronal PLM 
expression is sufficient to reduce dendritic arborization and spine formation, hallmarks of 
neuropathology in patients with Rett syndrome.   
Dominant-negative mutation in FXYD2 (γ-subunit of Na+-K+-ATPase) causes defective 
routing to the plasma membrane and is the cause of primary renal hypomagnesemia (44). 
Increased MAT-8 (FXYD3) expression is associated with tumor progression in human breast, 
prostate and colorectal cancers (84).  Likewise, dysadherin (FXYD5) expression is altered in a 
wide variety of human cancers, including but not limited to breast, gastrointestinal stromal, head 
and neck, papillary thyroid, colorectal, non-small cell lung, and testicular cancers, and also 
epitheliod sarcoma and malignant melanoma (50). 
Future Directions 
 The physiological role of PLM on regulation of L-type Ca2+ channel needs to be 
established in its natural environment.  The stoichiometry of interaction between PLM and Na+-
K+-ATPase, PLM and Na+/Ca2+ exchanger, and PLM and L-type Ca2+ channel, remains to be 
determined in cardiac myocytes.  The role of PLM in regulating cardiac contractility in vivo, 
both in health and disease states, needs further investigation. This will likely require 
development of novel genetic models.  The effects of oxidative stress and NO on both PLM and 
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Na+-K+-ATPase are just beginning to be addressed.  For effective but specific drug targeting, the 
precise molecular interactions between PLM and Na+-K+-ATPase, and PLM and Na+/Ca2+ 
exchanger need to be mapped out. 
Conclusion 
 FXYD proteins are emerging not only as novel endogenous regulators of ion transport 
but also as important targets in many human diseases including neurological, cardiac and renal 
diseases and a wide variety of cancers.  Phospholemman (FXYD1) regulates Na+-K+-ATPase, 
Na+/Ca2+ exchanger and possibly L-type Ca2+ channel in the heart.  Its effects on in vivo cardiac 
contractility are complex and remain to be clarified.  When hearts are subjected to stress, 
phospholemman minimizes risks of arrhythmogenesis and preserves inotropy. Elucidating the 
mechanisms by which alterations or mutations of FXYD proteins are involved in human diseases 
will undoubtedly provide novel and rational therapeutic targets. 
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Figure Legends. 
Figure 1.  Molecular model of phospholemman.  Nuclear magnetic resonance studies of highly 
purified phospholemman in micelles revealed 4 helices of the protein with a single 
transmembrane domain (after Francesca Marassi)(23, 76). The FXYD motif is in the 
extracellular domain and the important serine63 and serine68 are in the cytoplasm. 
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Figure 2. Phospholemman co-localizes with α1-subunit of Na+-K+-ATPase. Indirect 
immunofluorescence of adult rat ventricular myocytes doubly labeled with mouse monoclonal 
antibody against α1-subunit of Na+-K+-ATPase (A) and rabbit polyclonal anti-PLM antibody (B) 
are shown.  Primary antibodies are visualized with Alexa Fluor 488-labeled goat anti-mouse IgG 
(A) and Alexa Fluor 594- labeled goat anti-rabbit IgG (B). Note the orange color in the merged 
image (C), indicating co-localization of PLM and Na+-K+-ATPase.   Bar = 5 µm. 
Figure 3. Cardiac excitation-contraction coupling.  Membrane depolarization is initiated by opening 
of the Na+ channel (not shown) with Na+ entry. Extracellular Ca2+ enters via L-type Ca2+ channel (ICa) 
and Na+/Ca2+ exchanger (NCX1), causing Ca2+ release from the ryanodine receptor (RyR) in the 
sarcoplasmic reticulum (SR). Ca2+ binds to troponin and initiates myofilament contraction.  During 
diastole, Ca2+ is pumped back to the SR by SR Ca2+-ATPase (SERCA) under the control of 
phospholamban (PLB). A small amount of Ca2+ is also taken up by the mitochondrial Ca2+ uniporter. 
The amount of Ca2+ that has entered during systole is extruded by Na+/Ca2+ exchanger and to a lesser 
extent, by sarcolemmal Ca2+-ATPase.  Na+ that has entered via Na+ channel and Na+/Ca2+ exchanger is 
pumped out by Na+-K+-ATPase. Repolarization is mediated by opening of K+ channels (only the 
transient outward K+ current Ito responsible for early repolarization is shown).  Phospholemman (PLM) 
associates with and is an endogenous regulator of Na+/Ca2+ exchanger, Na+-K+-ATPase and possibly L-
type Ca2+ channel.  Na+/Ca2+ exchanger is depicted as operating in the forward mode (Ca2+ efflux) in the 
sarcolemma and reverse mode (Ca2+ influx) in the t-tubules.  Broken arrows point to ion transporters, 
ion channels and myofilaments that are altered after myocardial infarction. 
Figure 4.  Effects of activation of Na+-K+-ATPase by phosphorylated phospholemman on β-
adrenergic response in vivo.  Shown are normalized in vivo hemodynamics (+dP/dt) of anesthetized 
wild-type (•; n=9) and phospholemman-null (; n=14) mice after stimulation with 25 ng of 
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isoproterenol. Note time-dependent decline of +dP/dt in wild-type but not phospholemman-null hearts.  
Phospholemman phosphorylated at serine68 activates Na+-K+-ATPase (17, 80), leading to decreases in 
[Na+]i in wild-type but not phospholemman-null cardiac myocytes (18, 80). 
Figure 5.  Effects of inhibition of Na+/Ca2+ exchanger by phosphorylated phospholemman on β-
adrenergic response in vivo.  Left ventricles of phospholemman-null (KO) mice are injected with 
recombinant adeno-associated virus, serotype 9, expressing either green fluorescent protein (GFP)(; 
n=5) or the phosphomimetic phospholemman S68E mutant (•; n=7). S68E mutant inhibits Na+/Ca2+ 
exchanger but has no effect on Na+-K+-ATPase (69, 70, 87).  Five weeks after virus injection, in vivo 
hemodynamics (+dP/dt) are measured in anesthetized mice (80).  Note with increasing doses of 
isoproterenol, KO-S68E hearts contract significantly better than KO-GFP hearts.  Since isoproterenol 
has no effect on Na+-K+-ATPase in phospholemman-null myocytes (17, 80), [Na+]i is similar between 
KO-S68E and KO-GFP hearts (data not shown).  Enhanced contractility in KO-S68E hearts is therefore 
due to inhibition of Na+/Ca2+ exchanger by the S68E mutant. 
 
 
